share_log
Reuters ·  May 8 16:45
Regenxbio: Sees Balance in Cash, Cash Equivalents and Marketable Securities of $380.5 Mln as of March 31, 2024 to Fund Its Operations Into 2026
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment